Related Experiment Videos
Human B-lymphotropic virus (human herpesvirus-6)
D V Ablashi1, S F Josephs, A Buchbinder
1Laboratory of Cellular and Molecular Biology, National Cancer Institute, Bethesda, MD.
Journal of Virological Methods
|September 1, 1988
Summary
Human B-lymphotropic virus (HBLV), or human herpesvirus-6, shows broad tropism and is linked to various conditions. Further research is needed to understand its role in diseases and potential impact on HIV-1 immunodeficiency.
Area of Science:
- Virology
- Immunology
- Oncology
Background:
- Human B-lymphotropic virus (HBLV), also known as human herpesvirus-6 (HHV-6), was first identified in 1986.
- HBLV is biologically, immunologically, and molecularly distinct from other known human herpesviruses.
- The virus exhibits a wide tropism, infecting hemopoietic and neural cells.
Purpose of the Study:
- To investigate the pathogenicity of HBLV in various diseases.
- To explore the potential role of HBLV in exacerbating HIV-induced immunodeficiency.
- To develop diagnostic assays for HBLV detection and pathogenesis elucidation.
Main Methods:
- Isolation and characterization of HBLV.
- Prevalence studies of HBLV antibodies in different populations.
- Detection of HBLV-DNA in patient samples.
- In vitro co-infection studies with HBLV and HIV.
Main Results:
- HBLV antibody prevalence in the general population is 26%, with variations across groups.
- Elevated HBLV antibody titers are observed in patients with malignancies, Sjögren's syndrome, sarcoidosis, AIDS, and chronic fatigue syndrome.
- HBLV-DNA was detected in some B-cell lymphomas.
- In vitro co-infection with HBLV and HIV in CD4 cells enhances degeneration.
Conclusions:
- The broad tropism and serological evidence suggest HBLV may be pathogenic in certain diseases.
- HBLV co-infection might worsen HIV-induced immunodeficiency.
- Development of specific reagents and assays is crucial for HBLV detection and understanding its pathogenesis.